These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Is It Possible to Intervene in the Capacity of Ramírez-Toloza G; Aguilar-Guzmán L; Valck C; Menon SS; Ferreira VP; Ferreira A Front Immunol; 2021; 12():789145. PubMed ID: 34975884 [TBL] [Abstract][Full Text] [Related]
15. Molecular basis of Trypanosoma cruzi and Leishmania interaction with their host(s): exploitation of immune and defense mechanisms by the parasite leading to persistence and chronicity, features reminiscent of immune system evasion strategies in cancer diseases. Ouaissi A; Ouaissi M Arch Immunol Ther Exp (Warsz); 2005; 53(2):102-14. PubMed ID: 15928579 [TBL] [Abstract][Full Text] [Related]
16. Is the Antitumor Property of Trypanosoma cruzi Infection Mediated by Its Calreticulin? Ramírez-Toloza G; Abello P; Ferreira A Front Immunol; 2016; 7():268. PubMed ID: 27462315 [TBL] [Abstract][Full Text] [Related]
17. Rat models to investigate host macrophage defense against Trypanosoma cruzi. Fabrino DL; Leon LL; Genestra M; Parreira GG; Melo RC J Innate Immun; 2011; 3(1):71-82. PubMed ID: 21051863 [TBL] [Abstract][Full Text] [Related]
18. Trypanosoma cruzi infection by oral route: how the interplay between parasite and host components modulates infectivity. Yoshida N Parasitol Int; 2008 Jun; 57(2):105-9. PubMed ID: 18234547 [TBL] [Abstract][Full Text] [Related]
19. The Interactions of Parasite Calreticulin With Initial Complement Components: Consequences in Immunity and Virulence. Ramírez-Toloza G; Aguilar-Guzmán L; Valck C; Ferreira VP; Ferreira A Front Immunol; 2020; 11():1561. PubMed ID: 32793217 [TBL] [Abstract][Full Text] [Related]
20. [Immune response to Trypanosoma cruzi. An approach to the pathogenesis of Chagas' disease]. Braun M; de Titto E Acta Physiol Pharmacol Latinoam; 1985; 35(1):1-47. PubMed ID: 2932884 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]